Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Disposables Win Downstream
Single-Use Processes Replace Hard-Piped Operations for Many Companies
- Last year was a banner year for uptake in single-use products in biomanufacturing, but not so much for novel technology. “There’s nothing out there that wasn’t, in one form or another, in 2005,” says Vijay Singh, Ph.D. president, Wave Biotech LLC (www.wavebiotech.com). “What’s really changing is the acceptance level ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.